Manchester Capital Management’s Tetraphase Pharmaceuticals, Inc. TTPH Stock Holding History

Manchester Capital Management’s Portfolio TTPH Stock Details TTPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-749	Closed	-$20K	–	675
2019 Q1	$20K	Hold	749	–	–	﹤0.01%	516
2018 Q4	$53K	Hold	749	–	–	0.01%	346
2018 Q3	$41K	Hold	749	–	–	0.01%	372
2018 Q2	$53K	Hold	749	–	–	0.01%	355
2018 Q1	$46K	Hold	749	–	–	0.01%	361
2017 Q4	$94K	Hold	749	–	–	0.01%	287
2017 Q3	$102K	Hold	749	–	–	0.02%	265
2017 Q2	$107K	Hold	749	–	–	0.02%	268
2017 Q1	$138K	Hold	749	–	–	0.02%	232
2016 Q4	$60K	Buy	749 +374	+100%	+$29.6K	0.01%	329
2016 Q3	$29K	Hold	375	–	–	﹤0.01%	404
2016 Q2	$32K	Hold	375	–	–	﹤0.01%	410
2016 Q1	$35K	Hold	375	–	–	﹤0.01%	461
2015 Q4	$75K	Hold	375	–	–	0.01%	371
2015 Q3	$56K	Hold	375	–	–	0.01%	401
2015 Q2	$355K	Buy	+375	New	+$307K	0.06%	149
2014 Q2	–	Sell	-225	Closed	-$49K	–	1114
2014 Q1	$49K	Buy	+225	New	+$62.7K	0.01%	649

Other funds holding TTPH

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Manchester Capital Management's TTPH Position: Q2 2019 in Review

Manchester Capital Management sold out of Tetraphase Pharmaceuticals, Inc. (TTPH) in Q2 2019, closing a stake of 749 shares — an estimated $20K sold.

Manchester Capital Management first reported a position in TTPH in Q1 2014 and held it in 17 quarters. The position peaked at $355K in Q2 2015. 66 funds tracked by Wall St. Rank hold TTPH as of Q2 2019.

Manchester Capital Management reported no remaining Tetraphase Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Manchester Capital Management sold 749 Tetraphase Pharmaceuticals, Inc. shares in Q2 2019, an estimated $20K.
Manchester Capital Management first reported a position in Tetraphase Pharmaceuticals, Inc. in Q1 2014 and held it in 17 quarters.
Manchester Capital Management's Tetraphase Pharmaceuticals, Inc. position peaked at $355K in Q2 2015.
66 funds tracked by Wall St. Rank held Tetraphase Pharmaceuticals, Inc. as of Q2 2019.

Based on Manchester Capital Management's 13F filing for Q2 2019, filed 5 Aug 2019.